Tebipenem mechanism of action, indications, dosage, contraindications, risk factors
Reading File
Finding Sources
Searching the Web
tebipenem mechanism of action indications dosage contraindications 2024
Searching PubMed
tebipenem pivoxil oral carbapenem
Reading File
Reading Web Page
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/21…
I now have comprehensive data from the FDA label (June 2026), Medscape, and Katzung's pharmacology textbook. Here is the full profile:
Tebipenem (Utebzi) - Complete Drug Profile
Overview
Tebipenem pivoxil hydrobromide (brand name Utebzi) is the first orally bioavailable carbapenem antibiotic approved for use in adults. The FDA approved it in 2026. It is a prodrug that is rapidly converted to the active moiety, tebipenem, after oral administration.
Mechanism of Action
Tebipenem pivoxil is a prodrug - after oral ingestion, it is hydrolyzed in the gastric/intestinal fluid and by intestinal esterases in enterocytes to release the active form, tebipenem.
Tebipenem then crosses the outer bacterial membrane into the periplasmic space where it:
- Binds covalently (acylation) to penicillin-binding proteins (PBPs) - the enzymes responsible for the final cross-linking steps of peptidoglycan synthesis in the bacterial cell wall
- Inhibition of PBPs disrupts cell wall biosynthesis, weakening the peptidoglycan layer
- This leads to bacterial cell lysis and death (bactericidal)
PK/PD index: The pharmacodynamic driver is the fAUC₀₋₂₄/MIC ratio (free drug area under the curve to MIC), reflecting time-dependent killing characteristics. - FDA label for Utebzi
Resistance: Like other carbapenems, tebipenem is stable against most beta-lactamases but is degraded by serine carbapenemases and metallo-beta-lactamases. It does not require a dehydropeptidase inhibitor (unlike imipenem/cilastatin) because it is not significantly degraded by renal dehydropeptidase.
Spectrum of activity: Broad-spectrum gram-negative activity (Enterobacterales including ESBL-producers), some gram-positive coverage; active against organisms resistant to other oral antibiotics.
Indications (FDA-Approved)
Complicated Urinary Tract Infections (cUTI), including pyelonephritis in adults, caused by susceptible isolates of:
| Organism | Gram character |
|---|---|
| Escherichia coli | Gram-negative |
| Klebsiella pneumoniae | Gram-negative |
| Enterobacter cloacae species complex | Gram-negative |
| Klebsiella oxytoca | Gram-negative |
| Enterococcus faecalis | Gram-positive |
Key restriction: Only for patients who have limited or no alternative oral treatment options - tebipenem should not be used when other effective oral antibiotics are available, to limit the development of drug-resistant bacteria.
Dosage and Administration
Dosage form: Tablets, 300 mg tebipenem pivoxil each (green, round, film-coated; debossed "TBP" on one side, "300" on the other)
Administration: Can be taken with or without food.
Standard Dosing (Adults, eGFR 60-150 mL/min)
| Regimen | Detail |
|---|---|
| Dose | 600 mg (two 300 mg tablets) orally every 6 hours |
| Duration | 7 to 10 days |
Do not use beyond the recommended duration (carnitine depletion risk increases with prolonged use).
Renal Impairment Dose Adjustments
| eGFR (mL/min) | Dose | Frequency |
|---|---|---|
| 60 to <90 | 600 mg | Every 6 hours |
| 30 to 59 | 300 mg | Every 6 hours |
| 15 to 29 | 300 mg | Every 12 hours |
| >150 | Not recommended - decreased drug exposure may reduce efficacy | - |
Hepatic impairment: No dose adjustment required.
Pediatric use: Safety and efficacy not established in the USA (approved only for adults); pediatric data from Asia/other settings exist for some infections (e.g., 4 mg/kg BID studied in some countries).
Contraindications
- Hypersensitivity to tebipenem, tebipenem pivoxil, or any other beta-lactam antibacterial (penicillins, cephalosporins, carbapenems, monobactams)
- Primary or secondary carnitine deficiency, or inborn errors of metabolism that may result in clinically significant carnitine deficiency
Warnings, Precautions & Risk Factors
1. Hypersensitivity Reactions
- Serious and occasionally fatal anaphylactic reactions have been reported with beta-lactam antibiotics
- Cross-reactivity with penicillins: incidence is less than 1% but possible
- Discontinue immediately if allergic reaction occurs; initiate emergency treatment
- Before use: Ask about prior allergic reactions to beta-lactams
2. Seizures and Other CNS Adverse Reactions
- Like all carbapenems, tebipenem can cause seizures, encephalopathy, coma, asterixis, and myoclonic activity
- Risk is highest in patients with:
- Pre-existing CNS disorders (e.g., history of seizures, stroke, brain lesions)
- Renal impairment (drug accumulation)
- Elderly patients
- Postmarketing reports of seizures have been received
3. Carnitine Depletion (Pivoxil-related Risk)
- The pivoxil ester moiety generates pivalic acid as a byproduct, which binds carnitine and promotes its urinary excretion, depleting carnitine stores
- Carnitine is essential for fatty acid transport into mitochondria for energy metabolism
- Risks associated with carnitine depletion:
- Hypoglycemia (especially in children, elderly, and those with poor nutritional status)
- Metabolic disturbances
- Do not use beyond recommended treatment duration for this reason
- Contraindicated in patients already carnitine-deficient
- Do not co-administer with other pivalate-generating drugs (e.g., pivampicillin, cefditoren pivoxil)
4. Drug Interaction - Valproic Acid (High Risk)
- Co-administration with valproic acid (VPA) markedly reduces serum VPA levels, potentially below therapeutic range
- Mechanism: tebipenem promotes formation of VPA-glucuronide conjugates, accelerating VPA elimination
- This can lead to seizure breakthrough in epileptic patients on VPA
- Avoid the combination if possible; if unavoidable, monitor VPA levels and seizure activity very closely
5. Clostridioides difficile Infection (CDI)
- As with all antibiotics, C. difficile-associated diarrhea (CDAD) can occur, ranging from mild to life-threatening colitis
- Incidence: ~1% in clinical trials
- Consider CDI in patients who develop diarrhea during or after treatment
6. Interference with Newborn Screening Tests
- Important for pregnant patients: Maternal use of tebipenem pivoxil near delivery may result in elevated C5-acylcarnitine (C5OH) levels in newborn dried blood spot screening, potentially triggering false-positive results for isovaleric acidemia or other organic acidemias
- Inform neonatology/screening program if mother received the drug near delivery
7. OAT1/OAT3 Transport Inhibitors
- Drugs that inhibit renal OAT1 and OAT3 transporters (e.g., probenecid) can increase tebipenem plasma exposure - monitor for adverse reactions if combination is necessary
8. Development of Drug-Resistant Bacteria
- Prescribing tebipenem in the absence of proven or strongly suspected susceptible infections increases the risk of selecting resistant organisms
Adverse Effects
| Frequency | Effect |
|---|---|
| Diarrhea | 8% |
| Headache | 3% |
| Nausea | 1% |
| Abdominal pain | 1% |
| Elevated hepatic enzymes | 1% |
| C. difficile infection | 1% |
| <1% | Vomiting, dyspepsia, Candida infections (vulvovaginal, urinary, oral), rash, pruritus, urticaria |
| Postmarketing | Seizures, hypoglycemia with hypocarnitinemia |
Key Pharmacokinetic Facts
| Parameter | Value |
|---|---|
| Bioavailability | Oral (prodrug converted by intestinal esterases) |
| Tmax | 0.6-1.5 hours |
| Cmax | ~5 mcg/mL |
| Protein binding | ~42% |
| Volume of distribution | 66.4 L |
| Elimination | Renal |
Sources
- FDA Prescribing Information, Utebzi (June 2026)
- Medscape - Tebipenem Drug Reference
- Katzung's Basic and Clinical Pharmacology, 16th Ed. (Carbapenems chapter)
- Tebipenem: A Novel Oral Carbapenem - Semantic Scholar
Injection insulin icodec mechanism of action, indications, dosage, contraindications, risk factors
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.